Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8199801 | 1.00 | CA1 (0.58) | CA1CA2NFKB1CA4MAPT | |
| Hydrochloric Acid SCHEMBL27758218 | 0.98 | CA1 (0.56) | CA1CA2NFKB1CA4MAPT | |
| SCHEMBL6263656 | 0.86 | NFE2L2 (0.57) | CA1CA2NFKB1CA4MAPT | |
| SCHEMBL6263652 | 0.86 | NFE2L2 (0.57) | CA1CA2NFKB1CA4MAPT | |
| SCHEMBL8588159 | 0.86 | LMNA (0.45) | CA1CA2NFKB1CA4MAPT | |
| SCHEMBL15476799 | 0.84 | CA1 (0.62) | CA1CA2NFKB1CA4MAPT | |
| SCHEMBL28498 | 0.84 | CA1 (0.62) | CA1CA2NFKB1CA4MAPT | |
| SCHEMBL28499 | 0.84 | CA1 (0.62) | CA1CA2NFKB1CA4MAPT | |
| SCHEMBL31549899 | 0.84 | RAB9A (0.59) | NFKB1MAPTLMNASMN1; SMN2BCHE | |
| SCHEMBL4066791 | 0.83 | PTPN1 (0.54) | CA1CA2NFKB1CA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0051514-B1 | CINNAMOYL-CINNAMIC ACID DERIVATIVE, ITS PREPARATION AND ITS USE AS A THERAPEUTIC AGENT | SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: (FR) | 1983-11-23 | — | — | EP | claimed |
| JP-11080091-A | — | — | None | — | — | JP | disclosed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2000008023-A1 | CONDENSED TRICYCLIC PIPERIDINES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-17 | — | — | WO | disclosed |
| JP-H1180091-A | ALPHA-ACETYLCINNAMIC ACID DERIVATIVE, ULTRAVIOLET LIGHT ABSORBER, PREPARATION FOR EXTERNAL USE FOR SKIN AND HAIR COSMETIC CONTAINING THE SAME | KAO CORP | 1999-03-23 | — | — | JP | disclosed |
| US-4421927-A | SKIN DISORDERS | SOCIETE DE RECHERCHES INDUSTRIELLES (S.O.R.I.) (FR) | 1983-12-20 | — | — | US | disclosed |
| US-4414213-A | CARDIOVASCULAR DISORDERS | MEAD JOHNSON & COMPANY (US) | 1983-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | CA1 1769/4885CA2 4101/4885NFKB1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.